Eli Lilly and Co (Eli Lilly and Co) EBIT per Share

: $7.80 (TTM As of Dec. 2023)

View and export this data going back to 1970. Start your Free Trial

Eli Lilly and Co's EBIT per Share for the three months ended in Dec. 2023 was $2.93. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.80.

During the past 12 months, the average EBIT per Share Growth Rate of Eli Lilly and Co was 24.80% per year. During the past 3 years, the average EBIT per Share Growth Rate was 15.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 15.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Eli Lilly and Co's EBIT per Share or its related term are showing as below:

LLY' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.9 Med: 9.9 Max: 49.8
Current: 15.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Eli Lilly and Co was 49.80% per year. The lowest was -25.90% per year. And the median was 9.90% per year.

LLY's 3-Year EBIT Growth Rate is ranked better than
63.47% of 854 companies
in the Drug Manufacturers industry
Industry Median: 7.7 vs LLY: 15.30

Eli Lilly and Co's EBIT for the three months ended in Dec. 2023 was $2,647 Mil.

Eli Lilly and Co EBIT per Share Historical Data

The historical data trend for Eli Lilly and Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

6.06

8.32

7.13

7.89

7.79

Eli Lilly and Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share																2.41	1.81	2.45	0.61	2.93

Eli Lilly and Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Eli Lilly and Co's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	7040.5	/	903.284
=	7.79

Eli Lilly and Co's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2647	/	903.836
=	2.93

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.80

Eli Lilly and Co (NYSE:LLY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Eli Lilly and Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (Eli Lilly and Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

LLY:Mexico 1LLY:Italy LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Executives

Lilly Endowment Inc	10 percent owner	2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski	officer: Chief Accounting Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems	officer: SVP, ERM & CECO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson	officer: SVP and Pres., Lilly Bio-Meds	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White	officer: SVP & Pres-Lilly Oncology	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier	officer: EVP, HR & Diversity	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai	director
Mary Lynne Hedley	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van	officer: SVP, CEO LoxoONC, Pres LlyONC	C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau	officer: SVP & CIDO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez	officer: SVP & Pres., Mfg. Operations	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson	director	C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi	officer: SVP & CFO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017